New cholesterol drugs make strides in clinical trials
The excitement around PCSK9 – a promising new protein target for cholesterol-lowering therapies – appears to be justified. This week, at the American College of Cardiology’s annual meeting in Washington DC, several pharmaceutical companies presented data from advanced clinical trials showing that monoclonal antibodies that target and degrade PCSK9 are effective at treating patients with high cholesterol, especially when combined with statins such as Lipitor. Read more
Recent comments on this blog
Experiments reveal that crabs and lobsters feel pain
US research ethics agency upholds decision on informed consent
Chemistry credit disputes under the spotlight
Chemistry credit disputes under the spotlight
Contamination created controversial ‘acid-induced’ stem cells